InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,555.74
(
-0.16%
)
US TECH 100
19,023.16
(
-1.05%
)
Dow Jones
40,358.09
(
-0.14%
)
Brent Oil
81.10
(
0.40%
)
Bitcoin
66,452.20
(
0.80%
)
Post# of 252658
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120102
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 131019

Monday, 11/14/2011 11:46:30 AM

Monday, November 14, 2011 11:46:30 AM

Post# of 252658

My own view is that the 2.5mg [Xarelto] dose will cause more than 1% loss of overall US Lovenox sales attributable to ACS.

Just to be clear: the 1% absolute loss cited in the model in #msg-68940203 comes from a 10% loss in the ACS indication and a 10% segment weighting for ACS in the US Lovenox market—i.e. 10% x 10% = 1%.

If you think the 1% figure is too, how much higher do you think it should be?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up